Somai in collaboration with Lusófona University has published a groundbreaking peer-reviewed paper in Pharmaceuticals journal titled "Process Development for GMP-Grade Full Extract Cannabis Oil: Towards Standardized Medicinal Use."
The study validates Somai's patent-pending process for producing Full-Spectrum Extract Cannabis Oil (FECO), offering new scientific evidence that bridges pharmaceutical precision with consistent, patient-friendly formulations.
Key findings from the research include a standardized full-spectrum composition achieved through Somai's process of terpene extraction, deep-cooled ethanol extraction, and purification, which preserves the native cannabinoid and terpene profile of the plant throughout the production process. Enhanced patient experience was noted, as sensory analysis revealed higher acceptance ratings for Somai's purified FECO compared to crude extracts or competing products, with improvements in taste, color, and overall appearance making these preparations more tolerable and effective for patients. Scientific differentiation was also highlighted, with the research showing that the terpene fingerprint from the flower is remarkably preserved and can be controlled for reintroduction, emphasizing that terpene formulation is a science rather than guesswork.
"This paper underscores Somai's scientific leadership in the cannabis pharmaceutical industry," said Michael Sassano, Founder and Interim CEO of Somai. "Our study demonstrates that full-spectrum cannabis formulations can be scientifically structured, reproducible, and pharmaceutically precise—dispelling the misconception that full-spectrum must mean uncontrolled or inconsistent."
"This research is a step forward in establishing scientific rigor within the medical cannabis field," said Professor Maria do Céu Costa of Lusófona University. "Our findings show that with the right methodology, it is possible to preserve the integrity of the plant while achieving consistency, safety, and improved patient acceptance. It's a meaningful contribution to both science and therapeutic innovation."
Read the full text of the publication online at MDPI.
For more information:
Somai Pharmaceuticals
www.somaipharma.eu
